ReviewDiscover nano2026
Application of nanotherapy in cardiovascular diseases featuring novel pharmacological mechanisms and drug delivery strategies.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) remain the leading cause of death globally. However, conventional pharmacotherapy is often limited by poor targeting, low bioavailability, and systemic adverse reactions. Nanoformulations, including liposomes, polymeric nanoparticles, inorganic nanocarriers, biomimetic systems, and lipid-based carriers, have emerged as transformative platforms that enhance drug solubility, stability, and lesion-specific delivery. This review systematically summarizes the structural features, drug-loading mechanisms, and release strategies of these nanocarriers in major cardiovascular disease indications, such as atherosclerosis, myocardial infarction, hypertension, heart failure, and coronary artery disease. Relevant studies on nanoparticles loaded with Western drugs and traditional Chinese medicine monomers are discussed within a unified framework. Furthermore, this review addresses the limitations of endothelial permeability in cardiovascular tissues, translational barriers, and future directions for clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.